Trump targets senator over cannabis, GreenState reports
A GreenState report says President Trump singled out a U.S. senator over cannabis five days before the midterms. Key details remain unconfirmed.

Classic view of the historic US Capitol Building in Washington, DC, with a clear blue sky.
What the GreenState report establishes, and what it doesn't
GreenState's Oct. 29 'Legalization Nation' column reports that Trump targeted a senator over cannabis, but the available summary names no one.
The headline is the only confirmed content CannIntel has. It doesn't say which senator Trump went after, whether the attack came in a social media post, a speech or a campaign statement, or which cannabis issue prompted it.
That gap matters. CannIntel isn't going to characterize the senator's position, the president's motive or the policy at stake without the underlying text. Those details are the story. Filling them in by inference would be guesswork.
What can be said plainly: the report is dated Thursday, Oct. 29, 2026, and it concerns a sitting member of the U.S. Senate and a sitting president. We'll update this piece once the column's text, or a primary record of Trump's remarks, is in hand.
Why the timing raises the stakes
Federal midterm elections fall on Nov. 3, 2026, five days after the report, which turns any presidential comment on a senator into a campaign-season event.
A president publicly targeting a senator this close to Election Day is rarely a purely legislative act. Whether the senator is on the ballot this cycle is one of the first facts to verify. It determines whether this is a campaign attack or a policy fight carried out through the press.
Cannabis has become a cross-partisan issue in the Senate. Members of both parties have sponsored bills on banking access, rescheduling and veterans' access, and few of those bills have cleared the full chamber. The Senate Banking Committee advanced the SAFER Banking Act, which would give cannabis businesses access to financial services, by a 14-9 vote in September 2023. It never reached a floor vote.
Not yet resolved, in other words. Any new friction between the White House and a senator on cannabis lands on top of that unfinished record.
On the administrative side, the track is also open. The Drug Enforcement Administration (DEA) has been working through a proposal, first put forward by the Department of Justice in 2024, to move marijuana from Schedule I to Schedule III of the Controlled Substances Act. Schedule III placement would end the punishing application of Section 280E of the tax code to state-licensed operators, a change worth billions of dollars in annual tax relief across the industry. A dispute between the president and a senator over cannabis could bear on that process, on Congress's oversight of it, or on neither. The report as summarized doesn't say.
What operators, investors and policy staff should check next
Until the senator and the underlying cannabis issue are identified, the practical advice is to treat the report as a political signal, not a policy change.
Nothing in the available material suggests an executive order, a rule, a bill introduction or a committee action, and no new legal obligation for licensed operators follows from a headline alone. That's an important distinction for compliance teams and for investors who trade on federal reform headlines.
Here are the items worth confirming, in rough order of importance:
- The senator's name, committee assignments and whether the seat is up for election in 2026.
- The venue and exact wording of Trump's remarks, ideally from a transcript or the original post.
- Which cannabis issue was in play: rescheduling, banking, hemp-derived THC, state legalization or something else.
- Any follow-up from the senator's office or the White House.
Capitol Hill staff, not the market, usually read these moments first. Sponsors of pending cannabis bills will want to know if a presidential attack makes their cosponsors more or less willing to move legislation after the election, particularly in a lame-duck session when leadership typically has limited floor time.
One opinion, offered with the caveat that the facts are thin: a cannabis fight that surfaces five days before an election is more likely to reflect campaign positioning than a shift in federal drug policy. Operators shouldn't rebuild forecasts around it.
For full background on how the White House has handled the issue, see the CannIntel topic hub on Trump and cannabis politics.
Watch the primary record next: a transcript or post from Trump, and any response from the senator's office before polls open on Nov. 3. CannIntel will publish an updated report once either surfaces.
Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from News

Sudbury rescue group says dog cannabis poisonings at 'epidemic' level
A Sudbury animal rescue group is sounding an alarm over canine THC poisonings, but the public record on case counts is still thin.

Virginia Senator Faces Federal Marijuana and Fraud Charges
Marijuana Moment reported Oct. 22 that a top Virginia senator faces federal marijuana and fraud charges; the counts, court and named defendant await confirmation.

Virginia Sen. L. Louise Lucas indicted in marijuana business case
The Washington Post reported the indictment of Virginia's Senate president pro tempore, a figure in state cannabis debates. The charging details were not in the initial report.
More from the newsroom

Safe Harbor Financial Signs Opifex Media Term Sheet
SHF Holdings, doing business as Safe Harbor Financial, signed a non-binding term sheet for a combination with Opifex Media Inc., but no financial terms have surfaced.

NJCRC Approves Special Curaleaf Renewal, Denies Pesticide Request
New Jersey regulators granted Curaleaf an off-track renewal because of litigation and, in a separate ruling, rejected a pesticide-related request, Heady NJ reported.

ASA names 21 recipients of 2026 Cannabis Safety Awards
Americans for Safe Access tied its annual awards to the federal rescheduling debate, but the public excerpt omits recipients, categories and selection criteria.